Effect of Tang No.1 granule (糖1号方) in treating patients with impaired glucose tolerance

Yan Wei; Yu-zhi Hong; Xun Ye

doi:10.1007/s11655-008-0298-7

Your Location：

Home >

Browse articles >

Effect of Tang No.1 granule (糖1号方) in treating patients with impaired glucose tolerance

OriginalPaper | Updated：2021-08-27

- Effect of Tang No.1 granule (糖1号方) in treating patients with impaired glucose tolerance
- Effect of Tang No.1 granule (糖1号方) in treating patients with impaired glucose tolerance
- 中国结合医学杂志（英文版） 2008年14卷第4期页码：298-302
- Affiliations：
  
  Department of Endocrinology, Traditional Chinese Medicine Hospital of Hangzhou,Hangzhou,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-008-0298-7
  中图分类号：
- 纸质出版日期：2008，
  
  网络出版日期：2008-12-12，
Scan for full text
Wei, Y., Hong, Yz. & Ye, X. Effect of Tang No.1 granule (糖1号方) in treating patients with impaired glucose tolerance., Chin. J. Integr. Med. 14, 298–302 (2008). https://doi.org/10.1007/s11655-008-0298-7

Yan Wei, Yu-zhi Hong, Xun Ye. Effect of Tang No.1 granule (糖1号方) in treating patients with impaired glucose tolerance[J]. Chinese Journal of Integrative Medicine, 2008,14(4):298-302.
Wei, Y., Hong, Yz. & Ye, X. Effect of Tang No.1 granule (糖1号方) in treating patients with impaired glucose tolerance., Chin. J. Integr. Med. 14, 298–302 (2008). https://doi.org/10.1007/s11655-008-0298-7 DOI：

Yan Wei, Yu-zhi Hong, Xun Ye. Effect of Tang No.1 granule (糖1号方) in treating patients with impaired glucose tolerance[J]. Chinese Journal of Integrative Medicine, 2008,14(4):298-302. DOI： 10.1007/s11655-008-0298-7.

摘要

To observe the therapeutic effect of Tang No.1 granule (糖1号方

T1G) in treating patients with impaired glucose tolerance (IGT). Methods: One hundred and forty patients with IGT and with Pi (脾)-Wei (胃) dampness-heat syndrome type were assigned randomly according to their visiting sequence into two equal groups. The control group received only general knowledge about IGT

but to the treated group

based on current knowledge available

T1G was given additionally for 6 months. Changes in related laboratory indexes

including fasting plasma glucose and insulin (FPG and FINS)

plasma glucose 2 h after meal (2hPG)

glycosylated hemoglobin (HbA1c)

serum triglyceride (TG)

low density lipoprotein cholesterol (LDL) and insulin resistance index (HOMA-IR)

were observed. Results: The levels of FPG

2hPG

HbA1c

FINS

TG and HOMA-IR were significantly decreased after treatment in the treated group

showing a significant difference compared to the control group (P<0.01). Among them

HbA1c decreased from 7.08±1.41% to 6.56±1.29% in the treated group

while in the control group

it decreased from 7.02±1.37% to 6.93±1.31%. The level of LDL was also reduced in the treated group after treatment (P<0.05). In the treated group

13 out of 68 patients (19.12%) had their glucose tolerance reversed to normal

while in the control group

only 2/64 (3.1%) got it reverse; a comparison between the two groups in terms of reversion rate showed a significant difference (P<0.01). No severe adverse reaction was found in the therapeutic course. T1G has good clinical effect as a treatment intervention for IGT

as it could improve glycometabolism

significantly depress the levels of post-prandial blood sugar and blood lipids

alleviate clinical symptoms of patients

and effectively cut-off and reverse the yielding and development of diabetes mellitus.

Abstract

To observe the therapeutic effect of Tang No.1 granule (糖1号方

but to the treated group

based on current knowledge available

T1G was given additionally for 6 months. Changes in related laboratory indexes

including fasting plasma glucose and insulin (FPG and FINS)

plasma glucose 2 h after meal (2hPG)

glycosylated hemoglobin (HbA1c)

serum triglyceride (TG)

low density lipoprotein cholesterol (LDL) and insulin resistance index (HOMA-IR)

were observed. Results: The levels of FPG

2hPG

HbA1c

FINS

TG and HOMA-IR were significantly decreased after treatment in the treated group

showing a significant difference compared to the control group (P<0.01). Among them

HbA1c decreased from 7.08±1.41% to 6.56±1.29% in the treated group

while in the control group

it decreased from 7.02±1.37% to 6.93±1.31%. The level of LDL was also reduced in the treated group after treatment (P<0.05). In the treated group

13 out of 68 patients (19.12%) had their glucose tolerance reversed to normal

while in the control group

as it could improve glycometabolism

significantly depress the levels of post-prandial blood sugar and blood lipids

alleviate clinical symptoms of patients

and effectively cut-off and reverse the yielding and development of diabetes mellitus.

关键词

Tang No.1 granuleImpaired Glucose ToleranceClinical Observation

Keywords

Tang No.1 granuleImpaired Glucose ToleranceClinical Observation

references

Mitrakou A, Kelley D, Mokan M, et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992;326:22–29.

Shaw JE, Zimmet PZ, De Courten M, et al. Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius? Diabetes Care 1999;22:399–402.

Sicree R, Shaw JE, Zimmet PZ. The global burden of diabetes. In: Gan D, ed. Diabetes atlas. 2nd ed. Brussels: International Diabetes Federation, 2003:15–17.

Liao EY, Chao CS. Endocrinology. Beijing: People’s Medical Publishing Housing, 2001:1411–1418.

Zheng XY. Guiding principle of clinical research on new drugs of TCM. Beijing: China Medic-Pharmaceutical Sciences and Technology Publishing House, 2002: 233–237.

Chinasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486–494.

Ratner R, Goldberg R, Haffner S, et al. Impact of intensive lifestyle and metformin therapy on cardiovascuar disease risk factors in the diabetes prevention program. Diabetes Care 2005;28:888–894.

Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;18;(3):CD006063.

Pan XR, Li GW, Hu YH, et al. Effect of dietary and/or exercise intervention on incidence of diabetes in 530 subjects with impaired glucose tolerance from 1986–1992. Chin J Intern Med (Chin) 1995;34(2):108–112.

Yang WY, Lin LX, Qi JW, et al. The preventive effect of Acarbose and Metformin on the IGT population from becoming diabetes mellitus: a 3-year multicentral prospective study. Chin J Endocrinol Metab (Chin) 2001;17(3):7–10.

Shen YJ, Li YK. Pharmacology of Chinese materia medica. Shanghai: Shanghai Scientific and Technical Publishers, 1997:161,165.

Qian QH, Li YZ, Huang DH, et al. Effects of Sanhuang Xiaoke Capsule on insulin in rat model with type 2 diabetes resistance. J Shandong Univ Tradit Chin Med (Chin) 2005;29(5):392–394.

Zou WJ, Bai HY, Gao XP. The influence of P thomsonii Benth on insulin resistance induced by Dexamethasone. Chin Pharmacol Bull (Cjin) 2004;20(6):715–716.

Cheng YC, Qian QH, Mao C, et al. A clinical and experimental research on treating by replenishing qi and strengthening the spleen. J Shandong Univ Tradit Chin Med (Chin) 1994;18(1):21.

FULL TEXT LINK

More>

浏览量

375

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Clinical observation on treatment of Tourette syndrome by integrative medicine

Effect of Tongxie Yaofang (痛泻要方) Granule in treating diarrhea-predominate irritable bowel syndrome

Clinical observation on treatment of colonic cancer with combined treatment of chemotherapy and Chinese herbal medicine

Clinical observation on the effect of Zengse Pill (퓶즫취) in treating patients with vitiligo of qi-stagnancy and blood-stasis syndrome type

Effect of equiguard in treating patients with Shen-yang deficiency syndrome